Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J's Centocor Buy Eyes Potential $4 Bil. ReoPro Market To Spur Stent Sales

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's $4.9 bil. stock acquisition of biotechnology firm Centocor is motivated in part by the potential for Centocor's antiplatelet monoclonal antibody-based drug ReoPro (abciximab) to boost sales of coronary stents by J&J's Cordis unit.

You may also be interested in...

Centocor's ReoPro/Stent Combination Studies Could Be Attractive To J&J

Centocor's $250 mil. investment in studies to demonstrate the efficacy of its drug ReoPro in combination with coronary stents in percutaneous coronary interventions could be attractive to Johnson & Johnson, which reportedly has been in discussions to acquire the biotech firm.

QUOTED. 27 November 2020. Agam Sharda.

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts